Literature DB >> 29122079

Sinonasal T-cell expression of cytotoxic mediators granzyme B and perforin is reduced in patients with chronic rhinosinusitis.

Sarah E Smith1, Rodney J Schlosser, James R Yawn, Jose L Mattos, Zachary M Soler, Jennifer K Mulligan.   

Abstract

BACKGROUND: CD8+ T cells and natural killer (NK) cells are cytotoxic cells that use granzyme B (GrB) and perforin. Defective cytotoxic function is known to play a role in dysregulated immune response as seen in chronic sinusitis, also referred to as chronic rhinosinusitis (CRS). However, to our knowledge, in the United States, neither GrB or perforin expression has been reported in patients with CRS.
OBJECTIVE: The aim of this study was to investigate sinonasal cytotoxic cells, their mediators, and cell-specific distribution of these mediators in patients with CRS with nasal polyp (CRSwNP) and in patients with CRS without nasal polyp (CRSsNP).
METHODS: Blood and sinus tissue samples were taken from patients with CRSsNP (n = 8) and CRSwNP (n = 8) at the time of surgery. Control subjects (n = 8) underwent surgery for cerebrospinal fluid leak repair or to remove non-hormone-secreting pituitary tumors. The cells were analyzed via flow cytometry by using CD8 expression to identify cytotoxic T cells and CD56 expression to identify NK cells. Intracellular GrB and perforin expression were analyzed with flow cytometry.
RESULTS: We observed no significant differences in plasma or peripheral blood immune cell numbers or specific levels of GrB or perforin among the groups. In the sinonasal mucosa of the patients with CRSsNP and the patients with CRSwNP, there was a significant decrease in GrB and perforin levels (p < 0.05) despite similar or increased numbers of cytotoxic cells when compared with the controls. The overall decrease in GrB and perforin in the sinonasal mucosa of the patients with CRSsNP and the patients with CRSwNP was due to decreased T cell production. There was no difference in total NK cell count or expression of perforin or GrB among all the groups.
CONCLUSION: Total levels of sinonasal GrB and perforin were decreased in the sinonasal mucosa of both the patients with CRSwNP and the patients with CRSsNP compared with the controls, whereas sinonasal CD8+ T cells, (but not NK cells,), intracellular stores of GrB and perforin were reduced in the patients with CRSwNP compared with the controls.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29122079      PMCID: PMC5691237          DOI: 10.2500/ajra.2017.31.4474

Source DB:  PubMed          Journal:  Am J Rhinol Allergy        ISSN: 1945-8932            Impact factor:   2.467


  38 in total

1.  Pillars article: Perforin gene defects in familial hemophagocytic lymphohistiocytosis. Science. 1999. 286: 1957-1959.

Authors:  Susan E Stepp; Rémi Dufourcq-Lagelouse; Vinay Kumar
Journal:  J Immunol       Date:  2015-06-01       Impact factor: 5.422

2.  Natural killer cell activity in specific and non-specific bronchial challenge.

Authors:  E Vesterinen; T Timonen
Journal:  Ann Allergy       Date:  1988-03

3.  Accumulation of effector memory CD8+ T cells in nasal polyps.

Authors:  Harshita Pant; Amy Hughes; Dijana Miljkovic; Mark Schembri; Peter Wormald; Peta Macardle; Randall Grose; Heddy Zola; Doreen Krumbiegel
Journal:  Am J Rhinol Allergy       Date:  2013 Sep-Oct       Impact factor: 2.467

4.  CD4(+) and CD8(+) regulatory T cells in chronic rhinosinusitis mucosa.

Authors:  Harshita Pant; Amy Hughes; Mark Schembri; Dijana Miljkovic; Doreen Krumbiegel
Journal:  Am J Rhinol Allergy       Date:  2014 Mar-Apr       Impact factor: 2.467

5.  EPOS 2012: European position paper on rhinosinusitis and nasal polyps 2012. A summary for otorhinolaryngologists.

Authors:  Wytske J Fokkens; Valerie J Lund; Joachim Mullol; Claus Bachert; Isam Alobid; Fuad Baroody; Noam Cohen; Anders Cervin; Richard Douglas; Philippe Gevaert; Christos Georgalas; Herman Goossens; Richard Harvey; Peter Hellings; Claire Hopkins; Nick Jones; Guy Joos; Livije Kalogjera; Bob Kern; Marek Kowalski; David Price; Herbert Riechelmann; Rodney Schlosser; Brent Senior; Mike Thomas; Elina Toskala; Richard Voegels; De Yun Wang; Peter John Wormald
Journal:  Rhinology       Date:  2012-03       Impact factor: 3.681

6.  Role of interferon-γ-producing t cells in the pathogenesis of chronic rhinosinusitis with nasal polyps associated with staphylococcal superantigen.

Authors:  Kyu-Sup Cho; Chang-Su Kim; Hyun-Sun Lee; Su-Kil Seo; Hee-Young Park; Hwan-Jung Roh
Journal:  J Otolaryngol Head Neck Surg       Date:  2010-10

7.  Systemic monocyte-derived dendritic cells and associated Th2 skewing in chronic rhinosinusitis.

Authors:  Brendan P O'Connell; Rodney J Schlosser; Jennifer L Wentzel; Whitney Nagel; Jennifer K Mulligan
Journal:  Otolaryngol Head Neck Surg       Date:  2013-12-23       Impact factor: 3.497

8.  Granzyme B in atherosclerosis and transplant vascular disease: association with cell death and atherosclerotic disease severity.

Authors:  Jonathan C Choy; Paul C McDonald; Agripina C Suarez; Vivian H Y Hung; Janet E Wilson; Bruce M McManus; David J Granville
Journal:  Mod Pathol       Date:  2003-05       Impact factor: 7.842

9.  Differential expression of granzymes A and B in human cytotoxic lymphocyte subsets and T regulatory cells.

Authors:  William J Grossman; James W Verbsky; Benjamin L Tollefsen; Claudia Kemper; John P Atkinson; Timothy J Ley
Journal:  Blood       Date:  2004-07-06       Impact factor: 22.113

10.  Increased airway granzyme b and perforin in current and ex-smoking COPD subjects.

Authors:  Sandra Hodge; Greg Hodge; Judith Nairn; Mark Holmes; Paul N Reynolds
Journal:  COPD       Date:  2006-12       Impact factor: 2.409

View more
  1 in total

1.  A novel Granzyme B nanoparticle delivery system simulates immune cell functions for suppression of solid tumors.

Authors:  Xiaomin Qian; Zhendong Shi; Hongzhao Qi; Ming Zhao; Kai Huang; Donglin Han; Junhu Zhou; Chaoyong Liu; Yang Liu; Yunfeng Lu; Xubo Yuan; Jin Zhao; Chunsheng Kang
Journal:  Theranostics       Date:  2019-10-14       Impact factor: 11.556

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.